Industry M&A Weekly2026-09-09Nvidia’s $12.93B Hugging Face Bet, EverBank–WaFd’s $3.9B Merger, and Three More DealsFive disclosed transactions from September 3–9 show buyers bringing AI distribution, bank charters, oncology rights, and autonomous-driving software closer to the operating platform.
Industry M&A Weekly2026-09-02Aon's $17B USI Bet, Lilly's $2.875B Merida Buy, and Two More DealsA four-deal briefing on Aon's USI acquisition, Lilly's Merida buy, First Financial's bank merger, and BitGo's NYDIG trading-business acquisition, with value structures and strategic rationale.1
Industry M&A Weekly2026-08-26Industry M&A Weekly: McKesson's $2.25B Precision Buy, Roche's $2.3B Hanmi License, and Three MoreFive disclosed deals from August 19–26 show buyers paying for clinical-services platforms, cyber underwriting stacks, and late-stage biotech rights while most biotech headline totals stay tied to milestones and royalties.21
Industry M&A Weekly2026-08-19Industry M&A Weekly: Accelerant's $4B Take-Private, Stripe's Reported $7B OpenRouter Deal, and Four MoreSix transactions from August 12–19 show buyers consolidating specialty distribution, AI model access, and late-stage biotech assets while milestone terms shift part of the price into future regulatory and commercial risk.1
Industry M&A Weekly2026-08-12Industry M&A Weekly: Moneris' $1.44B Sale, Jazz's $1.32B Actio Deal, and Two MoreFour disclosed deals from August 5-12 show buyers paying for embedded payment rails, rare-disease programs, and medical-imaging component positions—while milestone and referral terms determine how much control and value change hands.
Industry M&A Weekly2026-08-05Industry M&A Weekly: Airtable's $1.28B Sale, J&J's $2.6B Sail Option, and Four MoreSix disclosed deals across enterprise software, biotech, and fintech show buyers paying for workflow control, clinical optionality, and faster capital recycling.
Industry M&A Weekly2026-07-29Industry M&A Weekly: Cyera's $1B Oasis Buy, argenx's $2.2B Forte Deal, and Two MoreA week-ending July 29 briefing on four disclosed transactions across AI security, biotech, oncology, and banking software, with deal structure, economics, buyer rationale, target technology, and cross-deal themes.
Industry M&A Weekly2026-07-22Industry M&A Weekly: Lilly's $3.8B AtaiBeckley Bet, Tempus-Personalis, and Two MoreA week-ending July 22 briefing on four disclosed biotech and diagnostics transactions, led by Lilly's up-to-$3.8 billion AtaiBeckley acquisition, with deal structure, buyer rationale, target technology, and cross-deal themes.
Industry M&A Weekly2026-07-15Stripe's $53B PayPal Offer, Avere's Reverse Merger, and Three More DealsA week-ending July 15 briefing on five disclosed or reported transactions across payments, AI software, and biotech, with deal structure, value, buyer rationale, and target technology.
Industry M&A Weekly2026-07-08Industry M&A Weekly: Vertex's $10B Crinetics Deal, AstraZeneca's $1.9B License, and Four MoreA week-ending July 8 briefing on six disclosed deals across biotech, fintech data, and healthcare software, led by Vertex's $10B Crinetics acquisition and AstraZeneca's $1.9B ex-China COPD license. The issue separates full acquisitions from strategic licenses and shows how buyers are adding specialized profit pools.
Industry M&A Weekly2026-07-01Industry M&A Weekly: Merck's $11.3B Bio-Techne Deal, Qualcomm's Modular Bet, and Four MoreA week-ending July 1 briefing on six disclosed deals and commitments across life-science tools, AI software, industrial data, digital engineering, payments, and AI power infrastructure.
Industry M&A Weekly2026-06-24Industry M&A Weekly: AbbVie’s $10.9B Apogee Bet and Four More DealsA week-ending June 24 briefing on five disclosed deals across biotech, fintech, and software, led by AbbVie’s $10.9B Apogee agreement and Biogen’s milestone-heavy RayThera acquisition. The issue separates clean deal values from private-company scale signals, then highlights how buyers are paying for workflow control and risk-data assets.
